Febuxostat Approval Still Leaves Many Questions For Lively Gout Market

FDA's mid-February approval of Takeda's oral gout drug Uloric (febuxostat) may have come as no surprise, given an advisory panel's positive recommendation in November, but the gout market itself could take some curious turns as therapy models shake out and other candidates line up for approvals